Coverage lines include products liability, cybersecurity and errors
and omissions
HARTFORD, Conn.–(BUSINESS WIRE)–The Travelers Companies, Inc. (NYSE TRV)
today announced a new comprehensive Life Sciences practice, which builds
on 35 years of industry experience, to offer insurance and risk
management solutions across the fields of pharmaceuticals, medical
devices and digital health, which includes health care IT, telemedicine
and medical software. Travelers now provides life sciences organizations
with access to multiple lines of coverage, including errors and
omissions, cybersecurity and industry-specific products liability,
including clinical trials.
“Technological and scientific innovations are transforming the way we
approach human health and are creating a new set of risks in Life
Sciences,” said Michael Thoma, Global Technology Chief Underwriting
Officer at Travelers. “Providing tailored solutions specific to this
industry will help our customers guard against the vulnerabilities they
may face throughout the product development lifecycle, from research and
clinical trials to production and distribution.”
Along with extensive knowledge and global capabilities, customers
benefit from:
For more information about Life Sciences products and services from
Travelers, please visit travelers.com.
About Travelers
The Travelers Companies, Inc. (NYSE: TRV)
is a leading provider of property casualty insurance for auto,
home
and business.
A component of the Dow Jones Industrial Average, Travelers has
approximately 30,000 employees and generated revenues of approximately
$30 billion in 2018. For more information, visit www.travelers.com.
Contacts
Media:
Kate Thermansen, 860.954.1789
ktherman@travelers.com
CHICAGO, July 4, 2024 /PRNewswire/ -- The global microscopy market is poised for significant growth, expected…
Toronto, Ontario--(Newsfile Corp. - July 4, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE)…
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL)…
SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free…
ICPO Center NuMeRI ICPO Foundation signed the contract with Nuclear Medicine Research Infrastructure (NuMeRI) to…
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…